Surgical IncisionEarly Phase 1NCT03561376
Zinc Oxide Versus Petrolatum Following Skin Surgery
A Early Phase 1 study testing Topical zinc oxide vs. petrolatum post-surgical scars in people with Surgical Incision and Surgery--Complications, run by Melissa Pugliano-Mauro at 1 site in United States.
Trial summary
Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Surgical Incision, Surgery--Complications, Surgical Wound
- What is being tested?
- Topical zinc oxide vs. petrolatum post-surgical scars
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2021to 30 Oct 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- ≥ 18 years of age
- Linear closure, non-scalp site
- ≥ 4.5 cm in length (final incision/closure length)
- End to end symmetry (surgical site is not grossly asymmetric from end to end)
- Grossly uninfected site
Who cannot join
- ≤ 18 years
- Visibly asymmetric linear scar
- Grossly infected surgical site
- History of allergy to topical zinc oxide
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UPMC Dermatology St. Margaret
Pittsburgh, PA, Pennsylvania, 15213
Caroline Kettering, MD, ketteringce@upmc.edu
Lauren Crow, MD
About this study
Official title: Zinc Oxide Versus Petrolatum Following Skin Surgery: A Head-to-head, Prospective, Split-scar Study
Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).
Read the detailed description
Patients who have undergone dermatologic excision for any indication with or without Mohs micrographic surgical technique and surgically closed in linear fashion with scar length of greater than or equal to 4.5cm on any site but the scalp will be approached for enrollment in the study. Any closure in which one half of the linear scar appears grossly unequal to or worse than the other (due to any number of causes, such as suture technique, etc.) will be excluded from the study. Any patient whose surgical procedure was deemed as having high risk of post-surgical infection would also be excluded from the study as well as those with known history of topical zinc allergy. Consent will be obtained with one of the trained co-investigators. Included in this consent will be consent to collection of basic patient medical data pertinent to wound healing/scar formation will be obtained, such as history of keloids, smoking, history of diabetes mellitus, history of cancer and/or on chemotherapy, history of transplant, and immunosuppressive status, etc. for the purposes of this research. Risk to patients using zinc oxide ointment has been deemed by the FDA as minimal. Of note, zinc oxide ointment currently is the gold standard treatment for erosive diaper dermatitis on newborns and infants. It is generally deemed safe clinically and its application to other clinical settings outside of diaper rash has not been explored.
Upon providing consent for the study, the patient's surgical closure will be demarcated with sterile inked pen and "V" will be drawn on one end and "Z" on the other. The control, standard of care petrolatum (i.e. Vaseline) will be applied to the side indicated by "V" and the experimental treatment zinc oxide will be applied to the "Z" side. As a general rule, if oriented longitudinally, "Z" will mark distal, "V" will mark proximal. If oriented horizontally (left to right), "V" will mark the left side, "Z" the right. The ointments and standard pressure dressing will be administered in clinic upon closure and consent/enrollment. Patients will be sent home with package containing standard wound dressing materials as well as both zinc oxide and petrolatum.
Patients will be sent home with instructions and wound care materials to perform the following: (1) Keep post surgical pressure dressing in place for 48 hours (2) Gentle soap and water cleansing after 48 hours once daily (3) With daily dressing changes self apply zinc oxide ointment to side indicated by "Z" and petrolatum (vaseline) to side indicated by "V" (3b) Patient will be encouraged to re-mark site Z and V to serve as reminder to enhance compliance (4) Patient will sign off on daily log twice: once upon application of zinc oxide to Z side and upon application of petrolatum to V side. (5) Patient will perform daily dressing changes as above for one month. The application of daily ointment with or without dressing is also routine standard of care at the present time. Draft of patient instructions has been included with this submission.
Patients will be seen at the routine standard of care visit 7 days post-op for suture removal. At this point in time, accompanying dressing will be taken down, cleansed with sterile saline, and patient wounds will be photographed under standardized conditions, with avoidance of any clue as to which ointment was applied to which side. In addition, patients will perform the patient portion of the POSAS (Patient and Observer Scar Assessment Scale v2.0, a validated measure of scar cosmesis, with 6 to 60 scale, with low numbers represent that scar appears most similar to normal skin, whereas 60 indicates that the scar is visually furthest from normal skin, i.e. worst possible scar). Patients will also follow-up at 4 weeks, 8 weeks, and 6 months post-operatively for scar assessment. Patient parking will be validated. For patients requesting optimal close clinical follow-up for post-surgical scars, this appointment schedule represents the highest standard of care. At these visits, photographs will be obtained, and patients will again be asked to complete the patient portion of the POSAS scale. Upon completion of the six month follow-up visit for this pilot study, patients will be given a basic skin care product sample gift bag, containing a standardized collection of samples of hypoallergenic washes and moisturizers. Of note, if a patient is unable to return for the final six month follow-up visit, patients will be allowed to submit electronic photographs (non-standardized, self taken) with clear instructions to send via secure message via MyUPMC, a secure interface allowing for communication between patient's and doctors within the UPMC (University of Pittsburgh Medical Center) network. This option is to be reserved as a last resort. Patients will not receive the gift bag if unable to return for this final study visit. Please note that patient obtained and entered photographs are routinely used clinically for remote assessment of skin disorders for routine clinical follow-up.
Board-certified dermatologists at the end of the study will evaluate the photographs obtained at a later point in the study. Through photographic and/or edited technique if necessary, they will be blinded to which side received zinc oxide and which side received petrolatum. Indeed, the POSAS has been validated with photographic use. In addition, an estimation of the linear proportion of epidermal seal will be evaluated visually based on clinical exam and/or photographs. Specifically, the length of the wound will be measured at this visit and distance of scar containing non grossly apposed skin edges will be measured. The sum of length of non-sealed areas within the V side and within the Z side will be calculated. In addition, clinical evidence of surgical site infection, wound disruption, and/or any other post-surgical complications will be documented.
Upon completion of study visits, POSAS score, epidermal seal, and other clinical data will be statistically analyzed. Compliance rates will be calculated. Primary outcome of POSAS vs. % epidermal seal will be utilized. A total of 30 participants has been established as a goal for this pilot study with guidance from the Clinical and Translational Science Institute at the University of Pittsburgh Medical Center.
The standardized post surgical scar assessment tool (SCAR, Scar Cosmesis Assessment and Rating) will be utilized to objectively record scar outcomes. In addition, photographs of the surgical sites will be taken at each visit. In exchange for their participation, all patient wound care materials will be provided by the clinic.
These research procedures will take place in the surgical suites of the UPMC Falk Dermatology Office Building and the UPMC St. Margaret's Dermatology Office Building. These activities are to take place during the 2018-19 academic year.
Clinical staff at both sites will be involved in the conduct of the study. Patients referred/scheduled to see faculty dermatologic surgeon Dr. Melissa Pugliano-Mauro will be the population pool.
- Conditions
- Surgical Incision, Surgery--Complications, Surgical Wound, Surgical Site Infection, Scar, Hypertrophic Scar
- Being tested
- Topical zinc oxide vs. petrolatum post-surgical scars
- Keywords
- Scar
- Medical subject headings
- Surgical Wound, Surgical Wound Infection, Cicatrix, Cicatrix, Hypertrophic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Topical zinc oxide vs. petrolatum post-surgical scarsDrug
Following linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be "split" and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery.
| Study group | Role | What they receive |
|---|---|---|
| Single arm - split scar study | Other | Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half Receives: Drug: Topical zinc oxide vs. petrolatum post-surgical scars |
What is being measured
The primary outcome is the main question the study is designed to answer.
POSAS (patient and observer scar assessment score)
Patient and observer scar assessment score. Range from 6-60. Higher score indicates greater patient satisfaction and better overall cosmesis of scar. Please note there is an observer and patient POSAS score. Both range from 6-60. The observer scale grades the apparent vascularity, pigmentation, thickness, relief, pliability, and surface area of the scar. The patient scale evaluate the patient's perception of pain, itching, color, stiffness, thickness, irregularity associated with the scar. Each item is graded from 1-10 for a combined minimum to maximum of 6-60.
Measured: 8 weeks
Percentage of epidermal linear seal
% of linear scar that has fully sealed across surgical defect based on visual inspection. 0-100%. Higher percentage reflects greater proportion of visually sealed epidermis upon surgical closure.
Measured: 1 week
POSAS (patient and observer scar assessment score) change between 8 weeks and six months
Will assess for change in POSAS between weeks 8 and six months follow-up. The score will range from 0-54
Measured: To be assessed at 8 weeks and six months post-operative follow-up
Change in % epidermal linear seal between weeks 1 and 4 post-operative
Will assess change in % linear epidermal seal between weeks 1 and 4. The score will range from 0-100%.
Measured: weeks 1 and 4 weeks post-operative
POSAS (patient and observer scar assessment score)
Range from 6-60. Higher score indicates greater patient satisfaction and better overall cosmesis of scar
Measured: Six months post-operative follow-up
Percentage of epidermal linear seal
% of linear scar that has fully sealed across surgical defect based on visual inspection. 0-100%. Higher percentage reflects greater proportion of visually sealed epidermis upon surgical closure.
Measured: 4 weeks
Secondary outcomes (1)
Surgical site infection
As above. Any erythema, pus formation, or skin changes necessitating topical or systemic antibiotics.
Measured: 1 week, 4 weeks, 8 weeks, six months post-operatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2018
- Study start1 Sep 2021
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Surgical IncisionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Split scar study (petrolatum vs. zinc oxide)
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Melissa Pugliano-Mauro
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Melissa Pugliano-Mauro, University of Pittsburgh
- Investigators
- Caroline Kettering, MD, Principal investigator, Resident Physician, PGY-3
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03561376
- Sponsor's protocol ID
- STUDY19050135
- Status last verified
- Aug 2026
- First submitted
- 7 May 2018
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Thompson CB, Wiemken TL, Brown TS. Effect of Postoperative Dressing on Excisions Performed on the Leg: A Comparison Between Zinc Oxide Compression Dressings Versus Standard Wound Care. Dermatol Surg. 2017 Nov;43(11):1379-1384. doi: 10.1097/DSS.0000000000001209.
PubMed 28654576Kantor J. The SCAR (Scar Cosmesis Assessment and Rating) scale: development and validation of a new outcome measure for postoperative scar assessment. Br J Dermatol. 2016 Dec;175(6):1394-1396. doi: 10.1111/bjd.14812. Epub 2016 Oct 17. No abstract available.
PubMed 27292082
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Zinc Oxide Versus Petrolatum Following Skin Surgery: A Head-to-head, Prospective, Split-scar Study
- ClinicalTrials.gov ID
- NCT03561376
- Acronym / sponsor ID
- STUDY19050135
- Conditions
- Surgical Incision, Surgery--Complications, Surgical Wound, Surgical Site Infection, Scar, Hypertrophic Scar
- Keywords
- Scar
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Melissa Pugliano-MauroUniversity, hospital or other
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Oct 2027 (estimated)
- First posted
- 19 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operative infections, linear density of epidermal seal will be assessed at the 1 week, 4 weeks, 8 weeks, and 6 months post-operative periods and compared between the two groups. Participants will have parking validated for all visits and upon completion of all portions of the study will receive a standardized skin care gift bag containing samples for hypoallergenic skin care products (washes, moisturizers, etc.).
Detailed description
Patients who have undergone dermatologic excision for any indication with or without Mohs micrographic surgical technique and surgically closed in linear fashion with scar length of greater than or equal to 4.5cm on any site but the scalp will be approached for enrollment in the study. Any closure in which one half of the linear scar appears grossly unequal to or worse than the other (due to any number of causes, such as suture technique, etc.) will be excluded from the study. Any patient whose surgical procedure was deemed as having high risk of post-surgical infection would also be excluded from the study as well as those with known history of topical zinc allergy. Consent will be obtained with one of the trained co-investigators. Included in this consent will be consent to collection of basic patient medical data pertinent to wound healing/scar formation will be obtained, such as history of keloids, smoking, history of diabetes mellitus, history of cancer and/or on chemotherapy, history of transplant, and immunosuppressive status, etc. for the purposes of this research. Risk to patients using zinc oxide ointment has been deemed by the FDA as minimal. Of note, zinc oxide ointment currently is the gold standard treatment for erosive diaper dermatitis on newborns and infants. It is generally deemed safe clinically and its application to other clinical settings outside of diaper rash has not been explored.
Upon providing consent for the study, the patient's surgical closure will be demarcated with sterile inked pen and "V" will be drawn on one end and "Z" on the other. The control, standard of care petrolatum (i.e. Vaseline) will be applied to the side indicated by "V" and the experimental treatment zinc oxide will be applied to the "Z" side. As a general rule, if oriented longitudinally, "Z" will mark distal, "V" will mark proximal. If oriented horizontally (left to right), "V" will mark the left side, "Z" the right. The ointments and standard pressure dressing will be administered in clinic upon closure and consent/enrollment. Patients will be sent home with package containing standard wound dressing materials as well as both zinc oxide and petrolatum.
Patients will be sent home with instructions and wound care materials to perform the following: (1) Keep post surgical pressure dressing in place for 48 hours (2) Gentle soap and water cleansing after 48 hours once daily (3) With daily dressing changes self apply zinc oxide ointment to side indicated by "Z" and petrolatum (vaseline) to side indicated by "V" (3b) Patient will be encouraged to re-mark site Z and V to serve as reminder to enhance compliance (4) Patient will sign off on daily log twice: once upon application of zinc oxide to Z side and upon application of petrolatum to V side. (5) Patient will perform daily dressing changes as above for one month. The application of daily ointment with or without dressing is also routine standard of care at the present time. Draft of patient instructions has been included with this submission.
Patients will be seen at the routine standard of care visit 7 days post-op for suture removal. At this point in time, accompanying dressing will be taken down, cleansed with sterile saline, and patient wounds will be photographed under standardized conditions, with avoidance of any clue as to which ointment was applied to which side. In addition, patients will perform the patient portion of the POSAS (Patient and Observer Scar Assessment Scale v2.0, a validated measure of scar cosmesis, with 6 to 60 scale, with low numbers represent that scar appears most similar to normal skin, whereas 60 indicates that the scar is visually furthest from normal skin, i.e. worst possible scar). Patients will also follow-up at 4 weeks, 8 weeks, and 6 months post-operatively for scar assessment. Patient parking will be validated. For patients requesting optimal close clinical follow-up for post-surgical scars, this appointment schedule represents the highest standard of care. At these visits, photographs will be obtained, and patients will again be asked to complete the patient portion of the POSAS scale. Upon completion of the six month follow-up visit for this pilot study, patients will be given a basic skin care product sample gift bag, containing a standardized collection of samples of hypoallergenic washes and moisturizers. Of note, if a patient is unable to return for the final six month follow-up visit, patients will be allowed to submit electronic photographs (non-standardized, self taken) with clear instructions to send via secure message via MyUPMC, a secure interface allowing for communication between patient's and doctors within the UPMC (University of Pittsburgh Medical Center) network. This option is to be reserved as a last resort. Patients will not receive the gift bag if unable to return for this final study visit. Please note that patient obtained and entered photographs are routinely used clinically for remote assessment of skin disorders for routine clinical follow-up.
Board-certified dermatologists at the end of the study will evaluate the photographs obtained at a later point in the study. Through photographic and/or edited technique if necessary, they will be blinded to which side received zinc oxide and which side received petrolatum. Indeed, the POSAS has been validated with photographic use. In addition, an estimation of the linear proportion of epidermal seal will be evaluated visually based on clinical exam and/or photographs. Specifically, the length of the wound will be measured at this visit and distance of scar containing non grossly apposed skin edges will be measured. The sum of length of non-sealed areas within the V side and within the Z side will be calculated. In addition, clinical evidence of surgical site infection, wound disruption, and/or any other post-surgical complications will be documented.
Upon completion of study visits, POSAS score, epidermal seal, and other clinical data will be statistically analyzed. Compliance rates will be calculated. Primary outcome of POSAS vs. % epidermal seal will be utilized. A total of 30 participants has been established as a goal for this pilot study with guidance from the Clinical and Translational Science Institute at the University of Pittsburgh Medical Center.
The standardized post surgical scar assessment tool (SCAR, Scar Cosmesis Assessment and Rating) will be utilized to objectively record scar outcomes. In addition, photographs of the surgical sites will be taken at each visit. In exchange for their participation, all patient wound care materials will be provided by the clinic.
These research procedures will take place in the surgical suites of the UPMC Falk Dermatology Office Building and the UPMC St. Margaret's Dermatology Office Building. These activities are to take place during the 2018-19 academic year.
Clinical staff at both sites will be involved in the conduct of the study. Patients referred/scheduled to see faculty dermatologic surgeon Dr. Melissa Pugliano-Mauro will be the population pool.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Split scar study (petrolatum vs. zinc oxide)
| Arm | Type | Receives |
|---|---|---|
| Single arm - split scar study | Other | Drug: Topical zinc oxide vs. petrolatum post-surgical scarsSurgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- ≥ 18 years of age
- Linear closure, non-scalp site
- ≥ 4.5 cm in length (final incision/closure length)
- End to end symmetry (surgical site is not grossly asymmetric from end to end)
- Grossly uninfected site
Key exclusion criteria (4 listed)
- ≤ 18 years
- Visibly asymmetric linear scar
- Grossly infected surgical site
- History of allergy to topical zinc oxide
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Topical zinc oxide vs. petrolatum post-surgical scarsFollowing linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be "split" and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery. | Drug | Single arm - split scar study |
Primary outcome
POSAS (patient and observer scar assessment score)
Time frame: 8 weeks
Patient and observer scar assessment score. Range from 6-60. Higher score indicates greater patient satisfaction and better overall cosmesis of scar. Please note there is an observer and patient POSAS score. Both range from 6-60. The observer scale grades the apparent vascularity, pigmentation, thickness, relief, pliability, and surface area of the scar. The patient scale evaluate the patient's perception of pain, itching, color, stiffness, thickness, irregularity associated with the scar. Each item is graded from 1-10 for a combined minimum to maximum of 6-60.
Percentage of epidermal linear seal
Time frame: 1 week
% of linear scar that has fully sealed across surgical defect based on visual inspection. 0-100%. Higher percentage reflects greater proportion of visually sealed epidermis upon surgical closure.
POSAS (patient and observer scar assessment score) change between 8 weeks and six months
Time frame: To be assessed at 8 weeks and six months post-operative follow-up
Will assess for change in POSAS between weeks 8 and six months follow-up. The score will range from 0-54
Change in % epidermal linear seal between weeks 1 and 4 post-operative
Time frame: weeks 1 and 4 weeks post-operative
Will assess change in % linear epidermal seal between weeks 1 and 4. The score will range from 0-100%.
POSAS (patient and observer scar assessment score)
Time frame: Six months post-operative follow-up
Range from 6-60. Higher score indicates greater patient satisfaction and better overall cosmesis of scar
Percentage of epidermal linear seal
Time frame: 4 weeks
% of linear scar that has fully sealed across surgical defect based on visual inspection. 0-100%. Higher percentage reflects greater proportion of visually sealed epidermis upon surgical closure.
1 secondary outcome
Surgical site infection
Time frame: 1 week, 4 weeks, 8 weeks, six months post-operatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Background: PubMed 28654576Thompson CB, Wiemken TL, Brown TS. Effect of Postoperative Dressing on Excisions Performed on the Leg: A Comparison Between Zinc Oxide Compression Dressings Versus Standard Wound Care. Dermatol Surg. 2017 Nov;43(11):1379-1384. doi: 10.1097/DSS.0000000000001209.
- Results publication: PubMed 27292082Kantor J. The SCAR (Scar Cosmesis Assessment and Rating) scale: development and validation of a new outcome measure for postoperative scar assessment. Br J Dermatol. 2016 Dec;175(6):1394-1396. doi: 10.1111/bjd.14812. Epub 2016 Oct 17. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Surgical Incision
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
RecruitingObservational study
Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
Surgical Site Infection
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
Not yet recruitingPhase 3
Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:
Next Generation Sequencing (NGS), Surgical Site Infection (SSI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Caroline Kettering, MD principal investigator
Resident Physician, PGY-3
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Topical zinc oxide vs. petrolatum post-surgical scars in people with Surgical Incision and Surgery--Complications, run by Melissa Pugliano-Mauro at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Caroline Kettering, MD (4126474200, ketteringce@upmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
POSAS (patient and observer scar assessment score) (time frame: 8 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03561376, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.